Aerpio pharmaceuticals says announced restructuring of licensing deal with unit of gossamer bio

Aerpio announces amended licensing deal with gossamer bio on its inflammatory bowel disease (ibd) product candidate gb004 (formerly akb-4924).aerpio pharmaceuticals inc - announced a restructuring of licensing deal with unit of gossamer bio.aerpio - terms of amended agreement include $15 million immediate payment to co, $90 million in milestone payments regarding regulatory approvals, commercial sales.aerpio pharmaceuticals - also eligible to receive tiered royalties on sales of licensed products at percentages ranging from low to mid-single digits.
GOSS Ratings Summary
GOSS Quant Ranking